文献速递淋巴瘤

慢性淋巴细胞白血病靶向治疗耐药:临床与诊断实践的现状与展望

Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
PubMed 文献 · Leukemia · 2025-06-24

综述总结慢性淋巴细胞白血病(CLL)靶向治疗耐药的临床研究证据与生物学机制,涵盖BTK、PLCG2和BCL2等基因变异的检测方法、结果解读挑战及临床意义,以助力个体化治疗策略。

要点

  • BTK与BCL2抑制剂改善CLL结局,但耐药仍致治疗失败和疾病进展。
  • BTK、PLCG2和BCL2突变等耐药相关基因检测可能日益成为临床常规。
  • 综述汇总遗传与非遗传耐药机制、检测方法及结果解读挑战。

核心结论

  • 靶向治疗耐药是CLL治疗失败和疾病进展的主要原因,识别遗传性耐药有助于指导个体化治疗并改善患者结局。

研究设计与样本

  • 综述总结临床研究证据,并检视遗传性与非遗传性耐药的生物学机制。

主要发现

  • BTK与BCL2抑制剂整合入CLL治疗带来临床结局显著改善,包括生存期延长和生活质量提升。
  • 相当比例患者仍因靶向治疗耐药出现治疗失败和疾病进展。
  • 综述概述了检测靶向治疗耐药相关基因变异的方法学,并讨论了结果解读及解读挑战。
  • 综述探讨了识别遗传性耐药对指导个体化治疗策略的临床意义。

关键数值与推荐

  • 耐药相关基因变异包括BTK、PLCG2和BCL2突变。

临床怎么用

  • 原文指出,针对BTK、PLCG2和BCL2突变等耐药相关遗传变异的诊断检测可能日益成为临床常规实践的一部分。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The integration of BTK and BCL2 inhibitors into the treatment of patients with chronic lymphocytic leukemia (CLL) represents a paradigm shift and has led to significant improvements in clinical outcomes, including prolonged survival and enhanced quality of life. However, despite the efficacy of these agents, resistance to targeted therapy remains a major challenge, ultimately resulting in treatment failure and disease progression for a significant proportion of patients. Related to this, diagnostic testing for genetic variants associated with resistance, such as mutations in BTK, PLCG2 and BCL2, may become an increasingly common part of clinical routine practice. Addressing the need for placing the current knowledge in context, here we summarize the evidence from clinical studies and examine the underlying biology of both genetic and non-genetic resistance. Furthermore, we outline methodological approaches for the detection of gene alterations associated with targeted therapy resistance, discuss how to interpret these findings and highlight interpretation challenges. Finally, we offer insights into the clinical relevance of identifying genetic resistance to inform personalized treatment strategies and improve patient outcomes.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Blombery P, Chatzikonstantinou T, Gerousi M, et al. Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice. Leukemia. 2025. PMID: 40555733. doi:10.1038/s41375-025-02662-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。